Skip to main content
Clinical Trials/NCT01243138
NCT01243138
Completed
Not Applicable

Prevalence of Cardiovascular Risk Factors in Patients Attending General Practice Clinics in Selected Countries in the Africa and The Middle East Region

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.1 site in 1 country4,386 target enrollmentJuly 2011

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Obesity
Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Enrollment
4386
Locations
1
Primary Endpoint
Prevalence of cardiovascular (CV) risk factors such as obesity, smoking, dyslipidemia, diabetes mellitus and hypertension
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

This is a cross-sectional, epidemiological study to determine the prevalence of cardiovascular risk factors such as obesity, smoking, dyslipidemia, diabetes mellitus and hypertension in patients attending General Practice clinics in the Africa and Middle East region. A total of 4300 patients will be evaluated. In patients who are found to have previously been diagnosed with cardiovascular (CV) risk factors such as dyslipidemia or hypertension, the level of control of their respective conditions will also be evaluated.

Detailed Description

This is a cross-sectional, epidemiological study. In the course of this study, 4,300 persons from general practice, and other non specialist clinics of selected countries of the Africa and Middle East region, will be evaluated for the presence of cardiovascular (CV) risk factors such as obesity, smoking, dyslipidaemia, diabetes mellitus and hypertension. The degree of control of hypertension and dyslipidaemia in those previously diagnosed with these conditions will also be assessed. All medications used for CV risk factor control will also be ascertained. Patient evaluation will be done by physicians in charge of the selected clinics (who will be trained for case report forms completion) over one visit, through history taking, clinical examination as well as laboratory investigations. Every fifth patient seen on a particular day, fulfilling the inclusion and exclusion criteria would be included in the study.

Registry
clinicaltrials.gov
Start Date
July 2011
End Date
April 2012
Last Updated
5 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Adult aged 18 or above

Exclusion Criteria

  • Pregnant women and/or lactating mothers
  • Subjects presenting with any life threatening disease/condition

Outcomes

Primary Outcomes

Prevalence of cardiovascular (CV) risk factors such as obesity, smoking, dyslipidemia, diabetes mellitus and hypertension

Time Frame: At the time of the first visit

Secondary Outcomes

  • Compare the prevalence of CV risk factors such as obesity, smoking, dyslipidaemia, diabetes mellitus and hypertension in the male and female population.(At the time of the first visit)
  • Stratifying the prevalence of CV risk factors such as obesity, smoking, dyslipidaemia, diabetes mellitus and hypertension by age groups.(At the time of the first visit)
  • Ascertain the level of blood pressure and lipids' control as per the European Society of Cardiology (ESC) guidelines in patients who have been previously diagnosed as hypertensive or dyslipidaemic.(At the time of the first visit)
  • Ascertain the most commonly used medications in those that have been previously diagnosed as diabetic, hypertensive or dyslipidaemic.(At the time of the first visit)
  • Compare the prevalence of cardiovascular (CV) risk factors such as obesity, smoking, dyslipidaemia, diabetes mellitus and hypertension in the urban and rural population.(At the time of the first visit)

Study Sites (1)

Loading locations...

Similar Trials